CUIMC Focal Therapy Registry
Columbia University Prostate Cancer Focal Therapy Registry
調査の概要
詳細な説明
The primary objective of this study is to evaluate surgical, oncologic, functional, and quality-of-life outcomes following focal treatment with high-intensity focused ultrasound (HIFU) or irreversible electroporation (IRE) in patients with localized prostate cancer. The study will assess the feasibility and efficacy of focal prostate tissue ablation using these treatment approaches.
Multiparametric MRI will be used to identify regions of interest within the prostate and to support treatment planning and targeting. The investigators aim to further characterize outcomes after focal ablation with HIFU and IRE, including treatment-related effects, cancer control, and patient-reported quality-of-life measures.
In addition, the study will examine factors associated with ablation success, including targeting strategy and post-treatment assessment methods. Follow-up biopsy protocols will also be evaluated to determine their role in assessing treatment efficacy and confirming lesion ablation after focal therapy.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10032
- 募集
- Columbia University Irving Medical Center
-
コンタクト：
- Izak Faiena
- 電話番号：212-305-0114
- メール：if2274@cumc.columbia.edu
-
主任研究者：
- Izak Faiena, MD, MSCR
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Organ-confined prostate adenocarcinoma diagnosed by MRI/ultrasound fusion biopsy within a multiparametric MRI derived region of interest
- Clinical stage T2cN0M0 (radiological T3a is permitted)
- Multi-parametric MRI at New York-Presbyterian hospital (NYPH) within the past 6 months demonstrating region of interest suspicion level 2 by the Prostate Imaging Reporting and Data System version 2.0 scoring criteria
Transrectal or transperineal ultrasound-guided biopsy with 10 template biopsy cores and 2 MRI-ultrasound fusion targeted biopsy cores from the above MRI-derived region of interest demonstrating:
- histologically confirmed prostate adenocarcinoma from targeted biopsy cores
- unilateral Gleason score 4+3 prostate adenocarcinoma
- Age 40 to 85 years of age
- Subjects choose to undergo focal therapy and decline alternative treatment (such as active surveillance, radical prostatectomy, radiation therapy, cryosurgery or hormone therapy)
- Signed informed consent
Exclusion Criteria:
- Any Gleason score 4+4 outside an MRI-identified region of interest
- Prostatic calcifications which in the opinion of the investigator would impede delivery of the energy to tumor in patients choosing HIFU
- Any medical condition that would compromise the subject's ability to safely participate in the study
- American Society of Anesthesiologists (ASA) criteria of IV or higher
- Active urinary tract infection
- Rectal fissure, fibrosis, stenosis, or other anatomic abnormality precluding insertion of transrectal device
- Active, uncontrolled inflammatory bowel disease
- Urinary tract or rectal fistula
- Previous urethral sling, artificial urinary sphincter, or penile prosthesis surgery
- Any contraindication to MRI (such as contrast allergy, sever claustrophobia, MRI-incompatible prosthesis)
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Failure free survival
時間枠：10 years
|
10 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。